ライフサイエンスコーパス: polyoma

1 Comparisons of polyoma and SV40 small T antigens implicate Abeta in the

2 kinase cascade and indicate that the similar polyoma and SV40 small T-antigens influence PP2A to acti

3 anglioside synthesis is poorly infectible by polyoma and SV40, but addition of the appropriate gangli

4 have also been identified in members of the polyoma- and adenovirus families.

5 Hsp70 chaperones play a role in polyoma- and papillomavirus assembly, as evidenced by th

6 ic Hsp70 chaperones efficiently disassembled polyoma- and papillomavirus-like particles and virions i

7 Lipid binding sites for polyoma are shown to be present in rough ER membranes, s

8 ars to be a safe and effective treatment for Polyoma BK nephropathy.

9 Polyoma BK virus produces an aggressively destructive ne

10 24.2%), flu-like syndrome (11.6% vs 14.1%), polyoma (BK) viremia (8.2% vs 11.1%), and herpes simplex

11 er hematopoietic cell transplantation (HCT), polyoma-BK virus is associated with hemorrhagic cystitis

12 uirement for upstream elements including the polyoma enhancer A-binding protein-3 site (-83 to -91) a

13 They also induced the expression of polyoma enhancer activator 3 (PEA3) and increased its DN

14 ed the OPN promoter through two of its PEA3 (polyoma enhancer activator 3) sites.

15 actors of the AML (core binding factor-alpha/polyoma enhancer binding protein 2) class are key transa

16 corticoid-response elements and multiple ets/polyoma enhancer-binding 3 elements, were identified.

17 tors of the acute myelogenous leukemia (AML)/polyoma enhancer-binding protein (PEBP2alpha)/core-bindi

18 nding factoralpha-1/acute myeloid leukemia 3/polyoma enhancer-binding protein 2alphaA/osteoblast-spec

19 erpes simplex thymidine kinase promoter with polyoma enhancers, inserted into two defined chromosomal

20 The combined induction of c-fos, c-jun, and polyoma enhancing activator-3 (pea-3) by H. pylori cause

21 e activity of activator protein-1 (AP-1) and polyoma enhancing activity-3/E26 virus (PEA3/ETS) transc

22 cells as essential effectors in eliminating polyoma-infected and polyoma-transformed cells in vivo.

23 specific CD8+ T cells freshly explanted from polyoma-infected mice, suggesting that a single TCR reco

24 In addition, polyoma-infected resistant mice possess a 10- to 20-fold

25 ted by antiviral CD8(+) T cells during acute polyoma infection and is responsible for down-regulating

26 Urological complications and polyoma infection were the most significant risk factors

27 like particles (VLPs) derived from the human polyoma JC virus.

28 Rb proteins with viral oncoproteins such as polyoma large T (PyLT) antigen and Adenovirus E1A.

29 NK-1 carbohydrate, and a vector encoding the polyoma large T antigen.

30 erences between the classical T=7 capsid and polyoma-like capsids were also identified.

31 he middle T antigen of the DNA tumour virus, polyoma, localization to membranes in a specific manner

32 In the mouse mammary tumor virus-Polyoma Middle T (MMTV-PyMT) model of luminal breast can

33 eloped, we use the mouse mammary tumor virus-Polyoma Middle T (MMTV-PyMT), which mimics RANK and RANK

34 addresses the role of the three isoforms in polyoma middle T (PyMT) and ErbB2/Neu-driven mammary ade

35 hamster ovary cells expressing Mgat3 and the polyoma middle T (PyMT) antigen have reduced cell prolif

36 In mouse mammary tumor virus-polyoma middle T (PyMT) breast cancer mouse model, SRC-1

37 blished cohorts of mouse mammary tumor virus-polyoma middle T (PyMT) PAR1(-/-) and PAR2(-/-) mice, co

38 ct of tumor- or stromal cell-derived CTSB on Polyoma Middle T (PyMT)-induced breast cancer progressio

39 d vessels and worsened hypoxia in orthotopic polyoma middle T Ag (PyMT) triple-negative breast cancer

40 of p110alpha blocks tumor formation in both polyoma middle T antigen (MT) and HER2/Neu transgenic mo

41 (PI3K), while breast cancer driven by either polyoma middle T antigen (MT) or HER2 is p110alpha depen

42 the consensus sequence of the viral hamster polyoma middle T antigen (pYEEI) were characterized.

43 instillation of an RCAS vector carrying the polyoma middle T antigen (PyMT) gene (RCAS-PyMT) induced

44 with FVB mice and then cross-bred with MMTV-polyoma middle T antigen (PyMT) mice to investigate the

45 Using the MMTV-Polyoma Middle T antigen (PyMT) mouse model of human duc

46 f transgenic mammary tumors caused by either Polyoma middle T antigen (PyMT) or activated Neu/ErbB2.

47 ic overexpression of c-myc, c-neu, c-ha-ras, polyoma middle T antigen (PyMT) or simian virus 40 T/t a

48 ith mammary gland-targeted expression of the polyoma middle T antigen (PyMT) transgene develop primar

49 n-A (Fet) in mammary tumorigenesis using the polyoma middle T antigen (PyMT) transgenic mouse model.

50 mouse model of metastatic breast cancer, the polyoma middle T antigen (PyMT) transgenic mouse.

51 mary tumor virus long-terminal region-driven polyoma middle T antigen breast cancer model.

52 rring carcinomas of the mammary (MMTV-driven polyoma middle T antigen model, PyVmT) and prostate (TRA

53 roducing basal cells on activation of either polyoma middle T antigen or ErbB2 signaling.

54 antigen, were found to uniformly express the polyoma middle T antigen protein as well as 2',3'-cyclic

55 ast, elevated levels of SnoN cooperated with polyoma middle T antigen to accelerate the formation of

56 were crossed with transgenic mice expressing Polyoma middle T antigen under the control of the mouse

57 Mice expressing Polyoma middle T antigen under the mouse mammary tumor v

58 Virgin females carrying the Polyoma middle T antigen uniformly developed multiple, b

59 cancer, MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen), with Cav-1 (-/-)-null mice.

60 urine mammary tumor virus promoter linked to polyoma middle T antigen, a transgene that leads to rapi

61 CEINGE cl3 cells, immortalized with polyoma middle T antigen, were found to uniformly expres

62 om transgenic mice expressing Neu, H-Ras, or polyoma middle T antigen.

63 y tumor progression in mice that express the Polyoma middle T antigen.

64 rived vector) carrying the gene encoding the polyoma middle T antigen.

65 We tested these findings in vivo in the Polyoma middle T mammary tumor model in which p21CIP1 wa

66 Here, we show in the Polyoma Middle T mammary tumor model that N-cadherin (Cd

67 spontaneous breast cancer development in the polyoma middle T model.

68 stasis in Cyp2c44(-/-) mice crossed onto the polyoma middle T oncogene (PyMT) background.

69 In the current study, we have analyzed, in polyoma middle T oncogene (PyMT)-derived mammary tumors,

70 y epithelium during tumor development in the polyoma middle T oncogene (PyVT) mouse mammary tumor mod

71 With the help of the polyoma middle T oncogene driven breast cancer mouse mod

72 the overexpression of myc, ras, her2/neu, or polyoma middle T oncogenes.

73 of breast cancer caused by expression of the polyoma middle T oncoprotein (PyMT) in the mammary epith

74 were protected from tumors initiated by the polyoma middle T oncoprotein (PyMT), which activates Ras

75 In tumors from mice expressing the polyoma middle T oncoprotein (PyVT) in the mammary gland

76 tricted peptide, MT389-397, derived from the polyoma middle T oncoprotein.

77 rast, PTP1B deficiency has no effect on MMTV-polyoma middle T tumorigenesis.

78 e oncogenic transgenes MYC and Kras(D12), or polyoma middle T, and introduced into the systemic circu

79 Previously, mouse mammary tumor virus-driven polyoma middle T-antigen (MMTV-PyV MT) transgenic mice c

80 In the polyoma middle T-antigen (PyMT) transgenic mouse model o

81 development in the mouse mammary tumor virus-polyoma middle T-antigen model.

82 d crossed with the Mouse Mammary Tumor Virus-Polyoma Middle T-Antigen mouse.

83 etion of CX3CL1 in HER2/neu mice, but not in polyoma middle T-antigen oncomice.

84 The progression of polyoma middle T-antigen oncoprotein-induced mammary car

85 ur progression by using mammary tumour virus-polyoma middle T-antigen transgenic (PyMT) mice as a mod

86 Polyoma middle T-induced mammary carcinomas lacking the

87 imental model of human hemangiomas, in which polyoma middle T-transformed brain endothelial (bEnd) ce

88 bEND.3 cells are polyoma middle T-transformed mouse brain endothelial cel

89 carcinogenesis in mouse mammary tumor virus-polyoma middle tumor-antigen transgenic (MMTV-PyMT(tg) o

90 Expression of thrombospondin-1 (TS1) in polyoma middle-sized T (tumor)-transformed mouse brain e

91 difier loci (Apmt1 and Apmt2) accelerate the polyoma Middle-T (PyVT)-induced mammary tumor.

92 enerated wild-type mouse mammary tumor virus/polyoma middle-T (WT/PyMT) and AIB3(+/-)/PyMT mice.

93 ed with mice expressing a dominant oncogene (polyoma middle-T antigen driven by the MMTV promoter, Py

94 mammary carcinogenesis using an orthotopic, polyoma middle-T antigen-driven model in Foxp3(DTR) knoc

95 the mouse mammary tumor virus (MMTV)-driven polyoma middle-T oncogene strain, which shows early onse

96 ta complexed with the phosphoserine motif in polyoma middle-T was determined to 2.6 A resolution.

97 red alone or with breast cancer cells (mouse polyoma-middle T virus or primary human IDC) in 3D micro

98 u to adenocarcinoma in widely used multistep polyoma-middle T-antigen transgenic mice.

99 One allograft was lost because of polyoma nephritis.

100 us agents including human herpes, hepatitis, polyoma, papilloma, and retroviruses, as well as Chlamyd

101 The fate of the genome of the polyoma (Py) tumor virus following integration in the ch

102 lograft dysfunction and failure, the risk of polyoma recurrence in a subsequent transplant is unknown

103 In the present study, we report that polyoma small T antigen (PyST) associates with DBC1 in m

104 a high affinity and selective binding of the polyoma small T antigen (PyST) with the transcription co

105 Polyoma small T antigen (PyST), an early gene product of

106 Enhancement of PP2A Abeta/Akt interaction by polyoma small T antigen increased turnover of Akt Ser-47

107 The oncoprotein polyoma small T interacts with PP2A to regulate survival

108 Interestingly, the polyoma small T-antigen (PyST), which shares with MTA bo

109 In addition, CD94/NKG2A(+) polyoma-specific CD8 T cells have a markedly enhanced ca

110 o Ag stimulation compared with CD94/NKG2A(-) polyoma-specific CD8 T cells.

111 We identified several novel polyoma-specific CD8(+) T cell epitopes in C57BL/6 mice,

112 These findings indicate that polyoma-specific CD8(+) T cells are armed with, but rest

113 results in deletion of Vbeta6 TCR-expressing polyoma-specific CD8+ CTL, which appear to be critical e

114 a cloning attempt, we discovered that while polyoma T antigen-positive Chinese hamster ovary cells (

115 ffectors in eliminating polyoma-infected and polyoma-transformed cells in vivo.

116 e syngeneic polyoma virus-infected cells and polyoma tumor cells.

117 tramer+CD8+ T cells efficiently infiltrate a polyoma tumor challenge to virus-immune mice.

118 hich appear to be critical effectors against polyoma tumorigenesis.

119 cytomegalovirus disease or infection, no BK/polyoma viral nephropathy, and no posttransplant prolife

120 Identification of risk factors for BK polyoma virus (BKPyV) without confounding by donor facto

121 This virus, termed cynomolgus polyoma virus (CPV), is antigenically and genomically re

122 e in control of viral pathogens including JC polyoma virus (JCV) infection.

123 , with human herpes virus 3 (HHV3), JC human polyoma virus (JCV), HHV1, HHV4, HHV7, HHV5 showing the

124 HHV5), human papilloma virus (HPV), human JC polyoma virus (JCV), human endogenous retrovirus group K

125 hat some cases may be associated with the JC polyoma virus (JCV), which is also known to be latent in

126 Both torque teno virus and Merkel cell polyoma virus (MCPyV) were detected frequently in health

127 er, which is associated with the Merkel cell polyoma virus (MCPyV).

128 Merkel cell polyoma virus (MCV) has been implicated in a majority of

129 Murine polyoma virus (MPyV) is a small DNA virus that induces t

130 Polyoma virus (PV) can cause interstitial nephritis and

131 Polyoma virus (Py) and simian virus 40 (SV40) travel fro

132 Polyoma virus (Py) differs from other small DNA tumor vi

133 In this study polyoma virus (Py) is used as a tool to better define th

134 Using mouse polyoma virus (PyV) as a model of low-level persistent v

135 cells transferred to SCID mice responded to polyoma virus (PyV) infection with T cell-independent (T

136 Using the mouse polyoma virus (PyV) persistent infection model, we recen

137 ighly susceptible to tumors induced by mouse polyoma virus (PyV), but CD8-deficient mice are resistan

138 Using mouse polyoma virus (PyV), we asked whether CD4(+) T cell help

139 Using mouse polyoma virus (PyV), we found that MHC class Ia-deficien

140 %), cytomegalovirus 66 (3.75%), and BK virus polyoma virus 20 (1.13%) was low.

141 nation inhibition antibodies to the human JC polyoma virus and from 369 Amerinds from 13 tribes for h

142 he frequencies of precursor CTL specific for polyoma virus and MT(389-397) peptide were similar, indi

143 on procedure has been devised and applied to polyoma virus based on this rationale.

144 Reactivation of BK polyoma virus can result in destructive viral allograft

145 Importantly, CD94/NKG2A(+) anti-polyoma virus CD8 T cells appear to be essential for Ag-

146 racting (p53-TAg) or noninteracting (p53 and polyoma virus coat protein) pairs of proteins, treatment

147 two other alternative reading frames of the polyoma virus early region.

148 TL to recognize cells infected with a mutant polyoma virus encoding a MT truncated just proximal to t

149 The polyoma virus enhancer (PyE) is capable of conferring in

150 otein-2, CCAAT/enhancer-binding protein, and polyoma virus enhancer-3.

151 on, a mouse model was developed using murine polyoma virus expressing a defined CD4(+) T-cell epitope

152 Patients who had polyoma virus inclusions in renal allograft biopsies wer

153 as a therapeutic option in the management of polyoma virus induced graft failure.

154 The median time of diagnosis of polyoma virus infection after transplantation was 9.5 mo

155 In summary, persistent polyoma virus infection both quantitatively and qualitat

156 Polyoma virus infection causes acute interstitial nephri

157 Asymptomatic polyoma virus infection documented by urine cytology or

158 One animal had diarrhea and polyoma virus infection in the smooth muscle cells of th

159 Although polyoma virus infection is being increasingly recognized

160 Polyoma virus infection is characterized by lymphocytic

161 Previous graft loss secondary to polyoma virus infection is not a contraindication to ret

162 the B cells (CD20) in renal allografts with polyoma virus infection of 21% (range, 5-40%) compared w

163 The lymphocytic infiltrates of six cases of polyoma virus infection were compared with six cases of

164 pression predisposes cynomolgus monkeys to a polyoma virus infection with clinical consequences quite

165 Late in polyoma virus infection, early-strand mRNA levels are do

166 ograft survival was seen in patients who had polyoma virus infection.

167 c T cells in allografts is characteristic of polyoma virus infection.

168 ersible graft failure is more prevalent with polyoma virus infection.

169 and enumerate MT389-397-specific CTL during polyoma virus infection.

170 There were 10 cases of polyoma virus infections in renal transplant recipients.

171 54 to evaluate a rise in creatinine revealed polyoma virus interstitial nephritis.

172 The BK polyoma virus is a leading cause of chronic post kidney

173 Polyoma virus is a potent oncogenic pathogen when inocul

174 The natural mouse pathogen polyoma virus is highly oncogenic in H-2k mice carrying

175 Importantly, infection with a polyoma virus lacking MT389-397 and mutated in an MT236-

176 identified as a binding partner of the mouse polyoma virus large T antigen and later shown to possess

177 Chi3l1 ablation in the polyoma virus middle T (PyMT) breast cancer model genera

178 on into the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyV-mT) transgenic model.

179 mors in the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyVT) genetic model is delayed b

180 gene knockout and mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT)-induced breas

181 growth factor receptors and proteins such as polyoma virus middle T antigen (MT).

182 titors in in vitro binding experiments using polyoma virus middle T antigen (MT).

183 itive cells (differentiated astrocytes) with polyoma virus middle T antigen (MTA).

184 (TK-/-) were crossed to mice expressing the polyoma virus middle T antigen (pMT) under the control o

185 Viruses encoding mouse polyoma virus middle T antigen (PyMT) induced tumors, wh

186 V-A-based RCAS vectors encoding either mouse polyoma virus middle T antigen (PyMT) or c-Myc to elasta

187 ed with the mouse mammary tumor virus (MMTV)-Polyoma virus middle T antigen (PyMT) or MMTV-c-Neu tran

188 (MMTV) promoter-driven Ptn expressed in MMTV-polyoma virus middle T antigen (PyMT)-Ptn mouse breast c

189 ssion using transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary g

190 erived from transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary g

191 Polyoma virus middle T antigen (PyVmT) is a powerful vir

192 e G11 PLAP transgene was introduced into the polyoma virus middle T antigen mammary tumor model.

193 nse, we engineered mouse mammary tumor virus-polyoma virus middle T antigen mice with endothelial cel

194 ery of avian retroviruses encoding the mouse polyoma virus middle T antigen to elastase-tv-a transgen

195 after the somatic introduction of the mouse polyoma virus middle T antigen to mice with liver-specif

196 c PET and diffusion-weighted (DW)-MRI in the polyoma virus middle T antigen transgenic mouse model of

197 kt levels in total mouse mammary tumor virus-polyoma virus middle T antigen tumor lysates, suggesting

198 Transgenic expression of the polyoma virus middle T antigen, under control of the mou

199 which activates the erythropoietin receptor; polyoma virus middle T antigen, which resembles an activ

200 in transgenic mice expressing the oncogene, polyoma virus middle T antigen.

201 limits mammary tumor initiation in the MMTV-polyoma virus middle T genetic model.

202 background of the mouse mammary tumor virus/polyoma virus middle T oncogene (MMTV-PyMT) mammary canc

203 metastases [mouse mammary tumor virus-driven polyoma virus middle T oncogene (MMTV-PyVT)].

204 were either crossed with mice expressing the polyoma virus middle T oncogene specifically in the mamm

205 mammary tumors due to the expression of the polyoma virus middle T oncogene.

206 nase signaling is the principle mechanism of polyoma virus middle T oncoprotein activation of c-fos e

207 oic acid inhibits transformation of cells by polyoma virus middle T oncoprotein.

208 of Src family kinases to membrane-associated polyoma virus middle T-antigen (PyMT) can result in the

209 l, we crossed MT1-MMP-deficient mice to MMTV-polyoma virus middle T-antigen (PyMT) mice.

210 We have isolated spontaneous mutants of polyoma virus middle T-antigen (PyMT) that do not activa

211 nd3, isolated from mice transformed with the Polyoma virus middle T-antigen is available commercially

212 Although polyoma virus middle T-driven tumors showed altered prim

213 of the late-appearing mammary tumors of MMTV-polyoma virus middle T;Nedd9(-/-) mice are characterized

214 hways that are influenced by IRS-1 using the polyoma virus middle-T (PyV-MT) transgenic mouse model o

215 The clinical course of patients with polyoma virus nephritis (PVN) is not well understood, pa

216 (n=7), T-cell-mediated rejection (n=4), and polyoma virus nephropathy (n=1).

217 ade in an attempt to reduce the incidence of polyoma virus nephropathy (PVAN).

218 Polyoma virus nephropathy after transplantation is belie

219 in a subset of renal allograft kidneys with polyoma virus nephropathy.

220 ivity and 57 days for patients who developed polyoma virus nephropathy.

221 me viremic and three patients (1%) developed polyoma virus nephropathy.

222 This effect did not occur with wild-type polyoma virus or RBCs expressing HEL alone.

223 This highly focused CTL response to polyoma virus provides a valuable animal model to invest

224 The polyoma virus region expressed early in the lytic cycle

225 Leflunomide inhibits Polyoma virus replication in vitro and closely monitored

226 Transformation of cells in culture by polyoma virus requires integration of signals downstream

227 DNA extracted from affected kidneys detected polyoma virus sequences using primers for a highly conse

228 The simian polyoma virus SV40 has been detected in specific human t

229 lations with no known exposure to the simian polyoma virus SV40, also were tested for antibodies to t

230 e a manifestation of the activity of a human polyoma virus termed "JC." Among a total of 1,835 person

231 JC virus (JCV) is a polyoma virus that commonly infects humans.

232 g stimulated by the middle T-antigen (MT) of polyoma virus to address this question.

233 Polyoma virus tubulo-interstitial nephritis-associated g

234 xic effector function in mice susceptible to polyoma virus tumorigenesis.

235 Polyoma virus type BK (BKV) nephritis has emerged as an

236 In the present study, a hitherto unknown polyoma virus was detected in 12 of 57 cynomolgus monkey

237 e formation of long-term humoral immunity to polyoma virus was intrinsic to B cells and was independe

238 Infection with a mutant polyoma virus whose MT is truncated just before the MT38

239 Polyoma virus, a highly oncogenic natural mouse DNA viru

240 acute and persistent phases of infection by polyoma virus, a mouse pathogen that is capable of poten

241 In mice infected by polyoma virus, a natural mouse pathogen that establishes

242 g infection and preventing tumors induced by polyoma virus, a natural murine papovavirus.

243 l CD8(+) T cells in mice acutely infected by polyoma virus, a persistent mouse pathogen, specifically

244 lation for long-term control of infection by polyoma virus, a persistent mouse pathogen.

245 control infection with the B-cell-dependent polyoma virus, because plasma cells were markedly absent

246 antigen (PyST), an early gene product of the polyoma virus, has been shown to cause cell death in a n

247 ific CD8(+) T cells following infection with polyoma virus, influenza virus, and Listeria monocytogen

248 Recently, a newly described polyoma virus, Merkel cell polyomavirus (MCPyV), was fou

249 approach is used to explain the structure of polyoma virus, Simian Virus 40 and L-A virus capsids, wh

250 are highly susceptible to tumor induction by polyoma virus, whereas C57BR/cdj (BR) mice are highly re

251 Because the course of polyoma virus-associated nephropathy (PVAN) has not been

252 d case of successful retransplantation after polyoma virus-induced renal allograft loss.

253 L/6 mice, a mouse strain highly resistant to polyoma virus-induced tumors.

254 neonates having opposite susceptibilities to polyoma virus-induced tumors.

255 IA-1: median, 7%; range, 2-15%) were seen in polyoma virus-infected allografts compared with 24% (ran

256 ) H-2k mice that specifically lyse syngeneic polyoma virus-infected cells and polyoma tumor cells.

257 Polyoma virus-infected MyD88 knockout mice generated str

258 characterize the lymphocytic infiltrates in polyoma virus-infected renal allografts.

259 Persistent anemia, polyoma virus-like nephritis (n = 2), and urinary calciu

260 In comparison to a case-matched polyoma virus-negative control group, the PVN patients w

261 During the persistent phase of infection, polyoma virus-specific CD8 T cells that express CD94/NKG

262 ion is associated with Ag-specific recall of polyoma virus-specific CD8 T cells.

263 ) T-cell help for generating and maintaining polyoma virus-specific CD8(+) T cells.

264 CD4(+) T-cell help for the H-2(b)-restricted polyoma virus-specific CD8(+) T-cell response during acu

265 ly identified the immunodominant epitope for polyoma virus-specific CTL as the Dk-associated peptide

266 ly identified the immunodominant epitope for polyoma virus-specific CTL in tumor-resistant H-2k mice

267 d in an MT236-244 Dk anchor position induced polyoma virus-specific CTL recognizing neither MT389-397

268 l responses in mice persistently infected by polyoma virus.

269 ding sites were found on middle T antigen of polyoma virus.

270 ex vivo cytolytic activity and clearance of polyoma virus.

271 y conserved region of the large T antigen of polyoma virus.

272 nation inhibition antibodies to the human BK polyoma virus.

273 viruses such as Zika, hepatitis B, Adeno and Polyoma virus.

274 and usually fatal CNS infection caused by JC polyoma virus.

275 including those from the herpes, retro-, and polyoma-virus families.

276 veloped fewer viral infections, particularly polyoma-virus-associated nephropathy (p = .021).

277 bition antibody titers against the JC and BK polyoma viruses (JCV and BKV, respectively) are signific

278 Capsids of papilloma and polyoma viruses (papovavirus family) are composed of 72

279 and origin-binding domains of papilloma and polyoma viruses evolved from a common ancestral protein

280 Although papilloma and polyoma viruses have differences in capsid size (approxi

281 ain significant antibody titers to the human polyoma viruses JC and BK but do not appear to contain e

282 The calcium bridge between the pentamers of polyoma viruses maintains capsid metastability.

283 rstanding the replication cycle of oncogenic polyoma viruses.

284 The crystal structure of polyoma VP1 with a sialic acid-containing oligosaccharid